Recursion Pharmaceuticals, Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
Shares declined 3.9% as investors responded negatively to cautious outlook signals and the lack of concrete near-term commercialization catalysts despite ongoing pipeline and partnership progress.
Key takeaways
- The company advanced five clinical-stage programs, including REC-4881 with promising Phase II data in a $10 billion FAP market lacking approved therapies.
- Partnership milestones included over $500 million in inflows and a new early discovery neuroscience program with Roche-Genentech, signaling validation of the AI platform but still at an early stage.
- REC-4881 expects additional Phase II data and FDA updates later this year; REC-1245 dose escalation and REC-7735 IND clearance position these assets for further clinical progress.
- Anticipated milestones include Sanofi candidate nomination and Phase I initiation for REC-7735, supporting pipeline depth but with no immediate revenue impact.
- Emphasis on scaling proprietary multimodal data and continuous model improvement underscores long-term ambitions, but tangible near-term growth drivers remain limited.
Q1 2026
May 8, 2026
Shares declined 3.0% following the earnings release as investors reacted to cautious progress without clear near-term commercial milestones, reflecting concern over execution pace and an extended runway despite expense cuts.
Key takeaways
- Established first clinical proof of concept with REC-4881 showing promising biological activity, but still early-stage with no commercial data.
- Pipeline breadth includes five wholly-owned programs with inflection points 12–18 months out, emphasizing a long timeline to potential catalysts.
- Partnered portfolio secured over $500 million in inflows with 10 milestones achieved, signaling progress but limited immediate revenue impact.
- Operating expenses reduced by 30% year-over-year, extending financial runway into early 2028, indicating ongoing capital discipline amid delayed commercialization.
- Focus remains on evolving an AI-driven drug discovery platform combining proprietary data, automation, and in-house compute, though tangible commercial value delivery remains to be demonstrated.
Q3 2025
Nov 7, 2025
Recursion's Q3 2025 earnings report reflects strong operational momentum, highlighted by a significant milestone payment from Roche and a sustained cash balance to support future initiatives under new CEO, Najat Khan.
Key takeaways
- Transition of leadership with Najat Khan stepping in as CEO on January 1, signaling a bold new strategic focus for the company.
- Achieved $30 million milestone payment from Roche, contributing to over $0.5 billion in total cash inflows from partnerships—a notable accomplishment for a pre-commercial biotech firm.
- Robust cash position of nearly $800 million, providing operational runway through 2027 without additional financing, enabling the pursuit of multiple upcoming catalysts.
- Continued advancements in the neuro map and microglial cell projects, critical for developing novel therapeutics in neuroscience and oncology.